Zobrazeno 1 - 10
of 223
pro vyhledávání: ''
Autor:
Jacopo Nanni, Cristina Papayannidis, Antonio Curti, Francesco Barbato, Stefania Paolini, Sarah Parisi, Michele Cavo, Francesca Bonifazi, Mario Arpinati, Gianluca Cristiano, Giovanni Marconi, Chiara Sartor
Publikováno v:
Acta Haematologica. 144:688-692
T-cell acute lymphoblastic leukemia (T-ALL) is a rare entity in the adult acute leukemia setting. Translocation (9;22)(q34;q11) and BCR-ABL1 rearrangement are occasionally found in T-ALL and have been reported in no more than 100 cases in the literat
Autor:
Noriaki Naeshiro, Hiroshi Aikata, Michio Imamura, Takashi Nakahara, Takayuki Fukuhara, Masataka Tsuge, Kazuaki Chayama, Yoji Honda, Keiichi Masaki, Eisuke Murakami, Yuki Yoshikawa, Tomokazu Kawaoka, Keiji Tsuji, Hideyuki Hyogo, Masami Yamauchi, Hatsue Fujino, Nami Mori, Y. Ogawa, Shinsuke Uchikawa, Kensuke Naruto, Akira Hiramatsu, Michihiro Nonaka, Yasuyuki Aisaka, Shoichi Takahashi, Yumi Kosaka, Yuwa Ando, Kei Morio, Takashi Moriya, Kei Amioka, Shintaro Takaki, Chihiro Kikukawa
Publikováno v:
Oncology. 99:507-517
Introduction: We evaluated the efficacy and safety of lenvatinib-transcatheter arterial chemoembolization (LEN-TACE) sequential therapy for patients (n = 88) with intermediate-stage hepatocellular carcinoma (HCC). Methods: Eighty-eight patients who o
Autor:
Sushmita Pathy, Ajay Kumar Yadav, Mukesh Yadav, Lalit Kumar, Sreenivas Vishnubhatla, Deepali Jain, Sachin Khurana, Anant Mohan, Prabhat Singh Malik
Publikováno v:
Oncology. 99:389-396
Background: Before the approval of first-line immune checkpoint inhibitors, platinum doublets were the standard of care in patients with treatment-naïve advanced non-small cell lung cancer (NSCLC) without targetable driver mutations. Pemetrexed-plat
Autor:
Atsushi Naganuma, Tamon Nagashima, Satoru Kakizaki, Daichi Takizawa, Hirotaka Arai, Ken Shirabe, Takeshi Hatanaka, Toshio Uraoka, Norifumi Harimoto, Takashi Ueno, Hiroki Tojima, Masashi Namikawa
Publikováno v:
Oncology. 99:641-651
Aim: Atezolizumab plus bevacizumab (atezo + bev) shows a good overall survival (OS) in advanced hepatocellular carcinoma (HCC) patients. However, the OS of patients with nonviral infection is quite worse than that in those with viral infection. The p
Autor:
Kazuhiro Kitajima, Hirotoshi Ishigaki, Takashi Yokoi, Ryo Takahashi, Hiroshi Doi, Toshiyuki Minami, Akifumi Nakamura, Yasuhiro Nakajima, Takashi Kijima, Yuichi Koda, Kozo Kuribayashi
Publikováno v:
Oncology. 99:161-168
Background: Cisplatin-pemetrexed combination chemotherapy is the current standard primary treatment for malignant pleural mesothelioma (MPM). It was first approved for untreated and unresectable MPM in the 2003 National Comprehensive Cancer Network (
Autor:
Savtaj S. Brar, Carol Jane Swallow, Charles Henry Lim, Hao-Wen Sim, Jennifer J. Knox, Bryan A. Chan, Akina Natori, James Brierley, Osvaldo Espin-Garcia, Rebecca Wong, Jolie Ringash, Eric Chen, Elena Elimova, Sara Hafezi-Bakhtiari, John Kim, Raymond Woo-Jun Jang, Di Maria Jiang, Geoffrey Liu, Patrik Rogalla, Gail Darling, Stephanie Moignard
Publikováno v:
Oncology. 99:49-56
Background: Trimodality therapy (TMT) with neoadjuvant chemoradiotherapy (nCRT) using concurrent carboplatin plus paclitaxel (CP) followed by surgery is the standard of care for locoregional esophageal or gastroesophageal junction (GEJ) cancers. Alte
Publikováno v:
Oncology. 99:105-113
Introduction: Cisplatin (CDDP)-induced nephrotoxicity is a concern in CDDP-based chemotherapy. The goal of this multicenter retrospective study was to identify potential risk factors for CDDP nephrotoxicity. Methods: Clinical data were reviewed for 7
Autor:
Junya Kitadani, Toshiyasu Ojima, Keiji Hayata, Hiroki Yamaue, Masaki Nakamura, Masahiro Katsuda, Mikihito Nakamori
Publikováno v:
Oncology. 99:57-61
Objectives: A regimen of S-1 combined with oxaliplatin (SOX) has been widely used as the first-line regimen for advanced gastric cancer. To further improve the antitumor efficacy for gastric cancer patients with peritoneal metastasis, we added nab-pa
Autor:
Keiji Yokoyama, Kazuhide Takata, Hideo Kunimoto, Hiromi Fukuda, Fumihito Hirai, Naoaki Tsuchiya, Satoshi Shakado, Takashi Tanaka, Daisuke Morihara, Ryo Yamauchi, Shotaro Sakisaka, Yasuaki Takeyama
Publikováno v:
Oncology. 98:779-786
Background and Aims: Lenvatinib is an oral anticancer drug for patients with unresectable advanced hepatocellular carcinoma (HCC). We evaluated whether a reduction in tumor stain at 2 weeks after lenvatinib treatment in patients with unresectable HCC
Autor:
Yosuke Suehiro, Hiroshi Aikata, Masataka Tsuge, Shinsuke Uchikawa, Yumi Kosaka, Akira Hiramatsu, Michio Imamura, Eisuke Murakami, Yuwa Ando, Kei Morio, Yasutoshi Fujii, Takashi Nakahara, K. Yamaoka, Kazuaki Chayama, Tomokazu Kawaoka, Shoichi Takahashi
Publikováno v:
Oncology. 98:727-733
Objective: Functional hepatic reserve is important when considering sequential tyrosine kinase inhibitor (TKI) therapy for patients with advanced hepatocellular carcinoma (HCC). We assessed albumin-bilirubin (ALBI) score and Child-Pugh class as indic